Register - event: Sept 22nd 6pm EDT: Saving Lives with Ovarian Cancer Prevention - An Update from the Ovarian Cancer Dream Team

 
Saving Lives with Ovarian Cancer Prevention - An Update from the Ovarian Cancer Dream Team

Registration is required to join this event. If you have not registered, please do so now.

Event status:

	Not started (Register)
Date and time:	Thursday, September 22, 2016 6:00 pm Eastern Daylight Time (New York, GMT-04:00) Change time zone
Duration:	1 hour
Description:	Join OCRFA and Dr. Elizabeth Swisher to hear about the exciting progress being made by the Stand Up to Cancer Ovarian Cancer Dream Team! The SU2C Ovarian Cancer Dream Team, funded by OCRFA and NOCC, got to work on year ago. Dr. Swisher, a gynecologic oncologist at the University of Washington and co-leader of the Dream Team, will update us on the progress the Team is making on this important and ambitious research project. About Dr. Elizabeth Swisher Elizabeth Swisher, MD, graduated cum laude from Yale University and received her medical degree from the University of California at San Diego. She completed her residency in obstetrics and gynecology at the University of Washington and a fellowship in gynecologic oncology at Washington University, St Louis. She joined the faculty at the University of Washington in 1999 where she is currently a Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology and an adjunct Professor in the Department of Medicine, Division of Medical Genetics. Both her clinical and laboratory work focus on cancer genetics. She is medical director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance. Her research has been funded by the NIH, the Department of Defense, the Ovarian Cancer Research Fund, and other cancer foundations. Dr. Swisher’s research has primarily focused on understanding the early events of ovarian carcinogenesis and on the development of novel biomarkers of disease and prognosis, with an emphasis on the role of the BRCA-Fanconi anemia pathway. She has been exploring how a better understanding of this pathway can lead to more effective therapies and prevention of ovarian cancers. She is principal investigator on several PARP inhibitor therapeutic trials and leads the translational research for numerous other clinical trials. Her overall goal is to reduce the burden of ovarian cancer by combining broader identification of inherited risk with effective prevention.